Clinical Trials Logo
  1. Home
  2. Carcinoma Breast Stage IV
  3. NCT02755272

A Study of Pembrolizumab With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Carcinoma Breast Stage IV Clinical Trial

Official title:
A Randomized Phase II Clinical Trial Assessing the Efficacy and Safety of MK-3475 (Pembrolizumab) in Combination With Carboplatin and Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer

Clinical Trial Summary

The main purpose of this study is to see if Pembrolizumab in combination with chemotherapy (carboplatin and gemcitabine) is safe and effective in treating patients with metastatic triple negative breast cancer. Pembrolizumab is a drug which may help the immune system to target and destroy cancer cells. Pembrolizumab has been approved by the FDA for the treatment of advanced melanoma and metastatic non-small cell lung cancer. However, it has not been approved as a treatment for breast cancer.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02755272
Study type Interventional
Source Fox Chase Cancer Center
Contact
Status Active, not recruiting
Phase Phase 2
Start date May 31, 2016
Completion date May 2026
View Details
See also
  Status Clinical Trial Phase
Completed NCT03511781 - Palliative Hypofractionated Radiotherapy in Advanced Incurable Breast Cancer N/A
Completed NCT00199212 - PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2 Phase 1
Recruiting NCT06281860 - Treatment Pleural Carcinosis of Pressurized IntraThoracic Hyperthermic Aerosol Cisplatin Administration Phase 1
Withdrawn NCT02140437 - Fulvestrant Combined Anastrozole Versus Anastrozole in Luminal A-like Postmenopausal ABC Phase 2
Terminated NCT02183805 - Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Metastatic Triple-negative Breast Cancer Phase 2
Terminated NCT01531764 - BIBW 2992 (Afatinib) and Vinorelbine Phase 2
Completed NCT00669565 - Safety and Efficacy Study of Bavituximab Plus Paclitaxel and Carboplatin to Treat Breast Cancer Phase 2
Completed NCT01631552 - Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Phase 1/Phase 2
Withdrawn NCT01906112 - Role of Surgery for the Primary in Patients With Breast Cancer Stage IV. Phase 3
Recruiting NCT02161315 - Steroid Aromatase Inhibitors Versus Progestogens for nSAID-resistanced Late Stage Breast Cancer N/A
Completed NCT00433095 - Vinorelbine (Oral) Plus Trastuzumab for 1st-line Treatment of HER2/Neu Overexpressing Breast Cancer Phase 2